Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Disc Medicine presented positive Phase 2 data for DISC-0974 in myelofibrosis anemia at the EHA Annual Meeting, showing durable anemia responses across all patient subgroups. The RALLY-MF trial data showed 55% of non-transfusion dependent patients achieved major hemoglobin response, while 64% of low-burden transfusion dependent patients achieved transfusion independence.
Key figures
- Drug Name
- DISC-0974, bitopertin, DISC-3405
- Phase Of Trial
- Phase 2
- Helios enrolled
- 86
- Rally mf enrolled
- 61
- Hepcidin reduction
- >75%
- Ntd major response rate
- 55%
- Ntd overall response rate
- 68%
- Bitopertin exposure duration
- 2.5+ years
- Rally mf responder analysis n
- 50
- Td low transfusion independence rate
- 64%
- Td high transfusion independence rate
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.